In the BioHarmony Drug Report Database
Dantrolene
Dantrium, Ryanodex (dantrolene) is a small molecule pharmaceutical. Dantrolene was first approved as Dantrium on 1982-01-01. It is used to treat cerebral infarction, cerebral palsy, malignant hyperthermia, multiple sclerosis, and muscle spasticity amongst others in the USA. The pharmaceutical is active against ryanodine receptor 1. In addition, it is known to target ryanodine receptor 3. Dantrolene sodium’s patents are valid until 2025-07-01 (FDA).
Trade Name
|
Dantrium, Ryanodex |
|---|---|
Common Name
|
dantrolene |
ChEMBL ID
|
CHEMBL1201288 |
Indication
|
cerebral infarction, cerebral palsy, malignant hyperthermia, multiple sclerosis, muscle spasticity, neuroleptic malignant syndrome, spinal cord injuries |
Drug Class
|
Image (chem structure or protein)